📊 SANA Key Takeaways
Is Sana Biotechnology, Inc. (SANA) a Good Investment?
Pre-revenue biotech company with negative $47.2M net income and $37.4M quarterly cash burn, resulting in approximately 2.2 years of runway at current burn rate. While improving diluted EPS suggests operational progress, the company lacks revenue generation and remains entirely dependent on clinical trial success with no near-term path to profitability.
Sana Biotechnology, Inc. Key Strengths (SANA)
- Positive cash position of $83.8M provides near-term operational runway
- Zero debt burden reduces financial risk and leverage
- Diluted EPS improved 17.2% year-over-year, indicating cost management improvements
SANA Stock Risks: Sana Biotechnology, Inc. Investment Risks
- Zero revenue with no visibility to near-term commercialization
- Quarterly cash burn of $37.4M leaves limited runway; dependent on continued financing
- Substantial liabilities of $254.4M relative to stockholders equity of $119.2M
- Entirely dependent on clinical trial outcomes; binary execution risk inherent in biotech development
Key Metrics to Watch
- Quarterly cash burn rate trend and cash runway extension
- Clinical trial progression, FDA milestone achievements, and regulatory pathway clarity
- Capital efficiency metrics and path to revenue generation from product candidates
Sana Biotechnology, Inc. (SANA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Sana Biotechnology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SANA Profit Margin, ROE & Profitability Analysis
SANA vs Healthcare Sector: How Sana Biotechnology, Inc. Compares
How Sana Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sana Biotechnology, Inc. Stock Overvalued? SANA Valuation Analysis 2026
Based on fundamental analysis, Sana Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sana Biotechnology, Inc. Balance Sheet: SANA Debt, Cash & Liquidity
SANA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sana Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.46 indicates the company is currently unprofitable.
SANA Revenue Growth, EPS Growth & YoY Performance
Sana Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
SANA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sana Biotechnology, Inc. (CIK: 0001770121)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SANA
What is the AI rating for SANA?
Sana Biotechnology, Inc. (SANA) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SANA's key strengths?
Claude: Positive cash position of $83.8M provides near-term operational runway. Zero debt burden reduces financial risk and leverage.
What are the risks of investing in SANA?
Claude: Zero revenue with no visibility to near-term commercialization. Quarterly cash burn of $37.4M leaves limited runway; dependent on continued financing.
What is SANA's revenue and growth?
Sana Biotechnology, Inc. reported revenue of N/A.
Does SANA pay dividends?
Sana Biotechnology, Inc. does not currently pay dividends.
Where can I find SANA SEC filings?
Official SEC filings for Sana Biotechnology, Inc. (CIK: 0001770121) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SANA's EPS?
Sana Biotechnology, Inc. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SANA's fundamental grade?
Based on our AI fundamental analysis in May 2026, Sana Biotechnology, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SANA stock overvalued or undervalued?
Valuation metrics for SANA: ROE of -39.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SANA's AI grade for 2026?
Our dual AI analysis gives Sana Biotechnology, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SANA's free cash flow?
Sana Biotechnology, Inc.'s operating cash flow is $-37.4M, with capital expenditures of $288.0K.
How does SANA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -39.6% (avg: 15%), current ratio 1.29 (avg: 2).